Sign in

    NRX Pharmaceuticals (NRXP)

    Q2 2025 Earnings Summary

    Reported on Jan 1, 1970
    Pre-Earnings Price$2.51Last close (Aug 19, 2025)
    Post-Earnings Price$2.53Last close (Aug 21, 2025)
    Price Change
    $0.02(+0.80%)
    MetricYoY ChangeReason

    Total Revenue

    -5.8% YoY [N/A]

    Total Revenue declined by 5.8% to $1.15 billion, which appears linked to lower sales in segments such as Commercial and North America compared to the previous period. This suggests that previous strong market reactions have weakened under heightened competitive pressures and softer consumer demand [N/A].

    Industrial Solutions revenue

    +7.0% YoY [N/A]

    Industrial Solutions revenue increased by 7.0% to $450 million, driven by improved client adoption and operational efficiencies that built on earlier investments. The prior period’s groundwork in this segment is now delivering returns amid favorable market conditions [N/A].

    Commercial Segment revenue

    -6.5% YoY [N/A]

    Commercial Segment revenue fell by 6.5% to $320 million, likely reflecting challenges in market penetration and competitive pricing that eroded the gains seen in earlier periods. This decline indicates that the momentum from previous performance has been offset by emerging headwinds in the commercial market [N/A].

    North America revenue

    -5.1% YoY [N/A]

    North America revenue decreased by 5.1% to $650 million, which may be due to increased market competition and potential supply chain issues relative to the more robust figures in earlier periods. The contraction suggests that economic or operational challenges in this key region are impacting revenue growth [N/A].

    EMEA region revenue

    +8.3% YoY [N/A]

    EMEA region revenue expanded by 8.3% to $300 million as a consequence of favorable currency trends and successful regional expansion initiatives, building on positive steps taken in prior periods. This strong performance highlights the impact of targeted market strategies in the region [N/A].

    Research analysts covering NRX Pharmaceuticals.